Abalos Therapeutics
Harnessing the power of arenaviruses in a differentiated immuno-virotherapy approach to fight cancer.
| EUR | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (18799 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | 19228 % | - | - |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Abalos Therapeutics GmbH is pioneering a novel approach to cancer treatment by leveraging the unique immune-stimulating properties of arenaviruses. The company operates in the biotechnology sector, focusing on developing innovative immuno-virotherapy solutions. Abalos targets cancer cells by using mammarenaviruses, which preferentially infect and proliferate within these cells, thereby inducing a robust and targeted immune response. This approach aims to activate all relevant immune cell types against both primary tumors and distant metastases.
The company's proprietary Fast Evolution Platform generates mammarenaviruses with optimized anti-tumoral properties, effectively reprogramming the immune system to eliminate malignant tumor tissue. Abalos serves a diverse range of clients, including healthcare providers, research institutions, and pharmaceutical companies, who are looking for cutting-edge cancer treatment solutions.
Abalos operates on a business model that includes research and development, clinical trials, and potential partnerships or licensing agreements with larger pharmaceutical companies. Revenue is generated through these partnerships, grants, and future sales of their therapeutic products once they receive regulatory approval.
Keywords: immuno-virotherapy, arenavirus, cancer treatment, mammarenaviruses, immune response, primary tumors, metastases, biotech, Fast Evolution Platform, oncology.